Novavax Q2 2024 GAAP EPS $0.99 Misses $1.64 Estimate, Sales $415.484M Miss $458.575M Estimate
Portfolio Pulse from Benzinga Newsdesk
Novavax (NASDAQ:NVAX) reported Q2 2024 earnings per share (EPS) of $0.99, missing the analyst consensus estimate of $1.64 by 39.63%. The company also reported quarterly sales of $415.484 million, which missed the analyst consensus estimate of $458.575 million by 9.40%. This represents a 2.11% decrease in sales compared to the same period last year.
August 08, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novavax reported Q2 2024 EPS of $0.99, missing estimates by 39.63%, and sales of $415.484M, missing estimates by 9.40%. Sales decreased by 2.11% YoY.
The significant miss on both EPS and sales estimates, along with a year-over-year decrease in sales, is likely to negatively impact NVAX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100